MEPED as salvage therapy for relapsed/refractory Hodgkin’s lymphoma incorporating edited non-oncogene addiction: mTOR as a bottleneck

Rescue therapies of relapsed/refractory (r/r) Hodgkin’s lymphoma (HL) in the third to sixth-line provide major, yet unresolved problems. The MEPED regimen includes nuclear receptor agonists such as pioglitazone and dexamethasone, which counterbalance HL homeostasis, HL stress response inhibitors, ev...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Dennis Christoph Harrer, Florian Lüke, Tobias Pukrop, Lina Ghibelli, Albrecht Reichle, Daniel Heudobler
Format:	Artigo
Jezik:	Inglês
Izdano:	Frontiers Media S.A. 2025-03-01
Serija:	Frontiers in Pharmacology
Teme:	relapsed/refractory Hodgkin’s lymphoma non-oncogene addiction mTOR M-CRAC Hodgkin’s lymphoma tissue editing anakoinosis
Online dostop:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1553331/full
Oznake:	Označite Brez oznak, prvi označite!